The US Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Amazon Health Services offers you curated choices, convenience, clarity of cost, and continuity of care on your path to get and stay healthy.

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

A device long used by adults to manage migraines was now available for children as young as eight years old, offering new ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

Periods are as natural as colds and fevers. This is a known fact: every woman experiences different kinds of pain and stress ...

Many people use the terms ‘migraine’ and ‘headache’ interchangeably. This leads many people to believe that migraines are not ...

The median income for middle-class Americans rose at an average rate of 1.2% per year from 1970 to 2000. The rate slowed to 0.3% per year from 2000 to 2018. The wealth of the top 1% continues to ...

After 3 months, 11 (39% ... Nikka et al., Pers. Comm.]. 1 Department of Neurology, Headache Centre & Pain Neuromodulation Unit, Fondazione Istituto Nazionale Neurologico Carlo Besta, Via Celoria ...

Migraines with brainstem aura are known by several different names: Aura symptoms may last between 5 minutes and 1 hour. When the headache starts, you might feel an intense throbbing or pulsating ...